The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Relief Therapeutics Holding's share price is CHF3.00.
Relief Therapeutics Holding's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was CHF0.32. Hence, Relief Therapeutics Holding's PS Ratio for today is 9.29.
Warning Sign:
Relief Therapeutics Holding SA stock PS Ratio (=4.47) is close to 1-year high of 4.8.
The historical rank and industry rank for Relief Therapeutics Holding's PS Ratio or its related term are showing as below:
XSWX:RLF'
s PS Ratio Range Over the Past 10 Years
Min: 2.08 Med: 32.65 Max: 2109.09
Current: 9.29
During the past 13 years, Relief Therapeutics Holding's highest PS Ratio was 2109.09. The lowest was 2.08. And the median was 32.65.
XSWX:RLF's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 9.155
vs XSWX:RLF: 9.29
During the past 13 years, Relief Therapeutics Holding's highest 3-Year average Revenue per Share Growth Rate was 175.10% per year. The lowest was -95.30% per year. And the median was 35.85% per year.
Back to Basics: PS Ratio
Relief Therapeutics Holding (XSWX:RLF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Relief Therapeutics Holding PS Ratio Related Terms
Relief Therapeutics Holding PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Relief Therapeutics Holding's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relief Therapeutics Holding PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's PS Ratio distribution charts can be found below:
* The bar in red indicates where Relief Therapeutics Holding's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Relief Therapeutics Holding's Share Price of today is CHF3.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Relief Therapeutics Holding's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was CHF0.32.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Relief Therapeutics Holding (XSWX:RLF) has a PS Ratio of 9.29 as of Jun. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Relief Therapeutics Holding and its competitors. This is 72% below median its historical median of 32.65. Over the past decade, Relief Therapeutics Holding's PS Ratio has ranged from 2.08 to 2,109.09.
Is Relief Therapeutics Holding's PS Ratio too high?
Relief Therapeutics Holding's current PS Ratio of 9.29 is 72% below median its 10-year median of 32.65. Over the past 10 years, this metric has ranged from a low of 2.08 to a high of 2,109.09. The Biotechnology industry median PS Ratio is 9.16. Relief Therapeutics Holding's value of 9.29 is 1.5% above this industry median. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's PS Ratio compare to KTTA and OSRH?
Relief Therapeutics Holding's PS Ratio of 9.29 can be compared against companies in the Biotechnology industry. The industry median PS Ratio is 9.16. Relief Therapeutics Holding's value of 9.29 is 1.5% above this benchmark. Historically, Relief Therapeutics Holding's own PS Ratio has ranged from 2.08 to 2,109.09 over the past decade. While the company's 10-year median is 32.65 vs. the industry median of 9.16, Relief Therapeutics Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.16, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Relief Therapeutics Holding's current PS Ratio of 9.29 is 1.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Relief Therapeutics Holding and its competitors. For the Biotechnology industry, the median PS Ratio is 9.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relief Therapeutics Holding's current PS Ratio is 9.29, which is 72% below median its own 10-year median of 32.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current PS Ratio of 9.29. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current PS Ratio is 9.29, which is 72% below median its 10-year median of 32.65 and 1.5% above the Biotechnology industry median of 9.16. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current PS Ratio is 9.29 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?
Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued.
The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.
Key valuation signals for XSWX:RLF:
PS Ratio: 9.29 (72% below median its 10-year median of 32.65)
GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
Industry Position: 1.5% above the Biotechnology median
No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score
Get the complete analysis for XSWX:RLF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RLF has been successfully added to your 
